CSPC PHARMA.

Established in 1997, China Shijiazhuang Pharmaceutical Group Co., Ltd. (CSPC) is a national innovative enterprise integrating R&D, production and sales of drugs, and with total assets of 41 billion yuan and 25,000 staffs.

CSPC is the first Chinese pharmaceutical enterprise which is oversea listed in HK stock market (01093.HK), until now its market value is more than HK$ 100 billion. What’s more, CSPC is the first pharmaceutical share since Hang Seng Index was found in the past 50 years.

CSPC is mainly engaged in developing, manufacturing and selling of pharmaceutical products. It has seven business segments: API, Generics, Innovative Drug, Anti-tumor Drug, Pharmaceutical Logistic, Massive health and Investment & Financing. Its products mainly include cardiovascular and cerebrovascular drug, antibiotic drug, vitamin, antipyretic and analgesic drug, digestive system drug and anti-neoplastic drug, etc., seven series in total and nearly 1,000 varieties, and the selling value of 30 more single-species have exceeded 100 million yuan. The products are sold around China and more than 100 countries and regions in the world.

In recent years, CSPC has achieved fast and sound development. In 2019, the Group achieved sales revenue of 36.456 billion yuan and paid various taxes of 3.04 billion yuan, making outstanding contributions to promoting the development of China's pharmaceutical industry and regional economic construction.

In the following years, driven by innovation and internationalization, CSPC will build itself the first“100 billion”pharmaceutical corporation in China step by step.